<DOC>
	<DOCNO>NCT00004496</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine maximum tolerate dose safety alpha-melanocyte stimulate hormone ( alpha-MSH ) patient acute renal failure . II . Determine safety pharmacokinetics alpha-MSH patient high risk acute renal failure renal transplantation . III . Determine safety pharmacokinetics alpha-MSH patient establish ischemic acute renal failure . IV . Determine effect alpha-MSH interleukin-10 pharmacokinetics .</brief_summary>
	<brief_title>Phase I Study Alpha-Melanocyte Stimulating Hormone Patients With Acute Renal Failure</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This dose escalation , double blind , placebo control , multicenter study . Group 1 : Patients infuse alpha-melanocyte stimulate hormone ( alpha-MSH ) placebo 5 minute . A cohort 5 patient infused dose level alpha-MSH minimum effective dose ( MED ) maximum tolerate dose ( MTD ) determine . Group 2 : Patients receive single dose MED alpha-MSH IV 5 minute time anastomose complete . Other patient receive alpha-MSH MTD . Cohorts 5 patient treat MED MTD . Group 3 : Patients receive alpha-MSH group 2 . Additional dose level also test . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>alpha-MSH</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<mesh_term>Melanocyte-Stimulating Hormones</mesh_term>
	<mesh_term>beta-Endorphin</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Group 1 : Patients chronic hemodialysis Group 2 : Patients high risk develop acute renal failure ( ARF ) cadaveric renal transplantation Received high risk allograft Cadaveric kidney great 24 hour cold ischemia time Donor rise creatinine organ procurement Donor 60 year Group 3 : Patients ischemic ARF due hypotension , surgery , trauma ARF severity index 2060 % Creatinine clearance 1214 mL/min Rising creatinine least 0.5 mg/dL per day 2 day without evidence recovery despite standard supportive care No drug contrast induce renal failure No oliguric renal failure ( creatinine clearance 34 mL/min ) No prior chronic renal failure Baseline creatinine great 2.5 mg/dL ( male ) 2.0 mg/dL ( female ) No ARF due bacterial fungal sepsis , nephrotoxin , acute tubulointerstitial nephritis , cyclosporine toxicity , bilateral renal vascular disease , systemic disease ( hepatorenal syndrome , glomerulonephritis , renal vasculitis , etc . ) Prior/Concurrent Therapy Group 1 : No recent immunosuppressive therapy Group 2 3 : No prior renal transplantation No prior alphaMSH Group 3 : No prior dialysis episode ARF No anticipate need dialysis least 24 hour At least 12 hour since prior diuretic , mannitol , dopamine At least 14 day since prior immunosuppressive drug Patient Characteristics No recent infection No know reaction Terumo T175 dialyzer Not prisoner Not pregnant nursing No allergy drug use study Not mentally impaired Group 3 : No severe nonrenal medical condition would interfere study ( e.g. , terminal cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 1999</verification_date>
	<keyword>acute renal failure</keyword>
	<keyword>rare disease</keyword>
	<keyword>renal genitourinary disorder</keyword>
</DOC>